Dr. Jean-Pierre Paccaud is heading the business development and corporate strategy activities of GARDP since January 2017, and contributed to its inception and setup. Previously, he was heading the business development and legal team of the Drugs for Neglected Diseases initiative (DNDi) since 2007. Prior to joining DNDi, Jean-Pierre founded in 2002 Athelas SA, a company active in the field of anti-bacterial drug discovery, which he lead until its merger with Merlion Pharmaceuticals in 2006. Previously, he spent more than 18 years in academia, working in immunology, diabetes, and cell biology, and was tenured at the University of Geneva School of Medicine. Trained as a molecular and cellular biologist, he earned his PhD at the University of Geneva School of Medicine, and completed his post- doctoral studies at the University of California at Berkeley in the laboratory of Prof. Randy Schekman.